Novel virus patients who received the microbiome immunity formula achieved complete symptom resolution, reduced proinflammatory markers, had increased favourable bacteria; and developed neutralising antibody.
Using big data analysis and metagenomics derived from novel virus patients, researchers in CU Medicine have developed a unique oral microbiome formula that targets gut dysbiosis. Clinical data showed the recovery of novel virus patients who received the microbiome immunity formula outperformed those with standard care in many aspects. These include the achievement of complete symptom resolution; significant reduction of proinflammatory markers in their blood, increase in favourable bacteria in their stool and development of neutralising antibody.
Only half of the patients in the group without the formula achieved this effect
|The First Week||The Second Week|
More﹕40% of Hong Kong People Show Gut Dysbiosis Comparable to that of Novel Virus Patients CUHK Microbiome Immunity Formula Hastens Recovery of Novel Virus Patients and Offers Hope to Boost Immunity